What is the growth forecast for the Human Granulocyte Colony-stimulating Factor market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Human Granulocyte Colony-stimulating Factor market?

Key drivers include rising cancer incidence and growing awareness of G-CSF therapy benefits, driving future outlook.

What are the challenges facing the Human Granulocyte Colony-stimulating Factor market?

Challenges include high development costs and stringent regulatory requirements, impacting market growth.

Which regions are leading the Human Granulocyte Colony-stimulating Factor market?

North America and Europe are leading the market, due to strong healthcare infrastructure and research initiatives.

Who are the top companies in the Human Granulocyte Colony-stimulating Factor market?

Top companies include Amgen, Pfizer, and Novartis, offering innovative G-CSF products and therapies.

How is technology impacting the Human Granulocyte Colony-stimulating Factor market?

Technology advancements are improving G-CSF production and purification, enabling more efficient and cost-effective manufacturing processes.

What is the current regulatory landscape for the Human Granulocyte Colony-stimulating Factor market?

The regulatory landscape is complex, with strict guidelines and regulations governing G-CSF development, approval, and marketing.

What is the market outlook for biosimilar G-CSF products?

The market outlook for biosimilar G-CSF products is promising, with increasing adoption and cost savings potential.

Why Is the Human Granulocyte Colony-stimulating Factor Market Growing So Fast? 2026 Analysis

Human Granulocyte Colony-stimulating Factor by Application (Hospital, Clinic), by Types (300μg/Dose, 150μg/Dose, 75μg/Dose, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Human Granulocyte Colony-stimulating Factor Market Size | CAGR 10.2 Forecast 2033

Why Is the Human Granulocyte Colony-stimulating Factor Market Growing So Fast? 2026 Analysis

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Human Granulocyte Colony-stimulating Factor Market Overview

The Human Granulocyte Colony-stimulating Factor market refers to the industry involved in the production and distribution of G-CSF, a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells. As a crucial component in the treatment of various diseases, including cancer and infectious diseases, the Human Granulocyte Colony-stimulating Factor market size is expected to experience significant growth. The growth outlook for this market is promising, with a projected market forecast of $1.4 billion by 2026, driven by increasing demand for effective treatments and industry expansion into new therapeutic areas, such as autoimmune disorders and infectious diseases.

Loading chart…

The current Human Granulocyte Colony-stimulating Factor market size is approximately $1.1 billion, with a growth forecast of 7.5% CAGR from 2026 to 2033. The market is driven by macro drivers such as increasing cancer incidence and advancements in biotechnology. Key forces shaping the industry include technology shifts towards biosimilars, regulations supporting the development of new treatments, and competitive intensity among market players. The largest region for the Human Granulocyte Colony-stimulating Factor market is North America, while the fastest-growing region is expected to be Asia-Pacific, driven by increasing healthcare expenditure and expanding patient population.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.61 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Chugai Pharmaceutical; Kyowa Hakko Kirin; Sanway; GenSci; SL PHARM; Kexing Bioproducts; Qilu Pharmaceutical; CSPC; Wuzhong Pharmaceutical; Quangang Pharmaceutical; Huabei Pharmaceutical; Harbin Pharmaceutical; Amoytop Biotech; Jiuyuan Gene Engineering; Four Rings Biopharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Human Granulocyte Colony-stimulating Factor market is poised for significant growth, driven by various factors. The market dynamics can be broken down into four key sections: Growth Drivers, Restraints, Opportunities, and Challenges.

Growth Drivers2 items

Increasing demand for Human Granulocyte Colony-stimulating Factor in the treatment of cancer and infectious diseases, driven by the rising prevalence of these conditions and the growing need for effective therapies, is expected to drive the Human Granulocyte Colony-stimulating Factor market size.

Advances in technology and manufacturing processes have improved the production efficiency and reduced the costs of Human Granulocyte Colony-stimulating Factor, making it more accessible to a wider range of patients and contributing to the growth forecast.

Restraints2 items

Stringent regulatory requirements and rigorous testing protocols can limit the entry of new players into the Human Granulocyte Colony-stimulating Factor market, potentially constraining market growth.

The high cost of research and development, combined with the risk of product failure, can deter companies from investing in the development of new Human Granulocyte Colony-stimulating Factor products, thereby hindering market expansion.

Opportunities2 items

Emerging markets in Asia and Latin America offer significant opportunities for growth, driven by increasing healthcare spending, improving infrastructure, and a rising demand for Human Granulocyte Colony-stimulating Factor therapies.

The development of biosimilars and generic versions of Human Granulocyte Colony-stimulating Factor products can increase market competition, drive down prices, and expand access to these therapies, contributing to the Human Granulocyte Colony-stimulating Factor market size.

Challenges2 items

The Human Granulocyte Colony-stimulating Factor market faces challenges related to product safety and efficacy, as well as the potential for adverse reactions and side effects, which can impact patient outcomes and market growth.

Intense competition among market players, combined with the need for significant investments in research and development, can create challenges for companies seeking to establish a strong presence in the Human Granulocyte Colony-stimulating Factor market and achieve a favorable growth forecast.

Market Segmentation

Loading chart…

The Application segment of the Human Granulocyte Colony-stimulating Factor market is a crucial aspect of market taxonomy. This segmentation category contributes significantly to the overall market size, as it encompasses various uses of Human Granulocyte Colony-stimulating Factor, including the treatment of cancer, HIV/AIDS, and severe chronic neutropenia. The application segment is further divided into subtypes, such as oncology and hematology, which are critical in determining the market size and growth prospects.

The Types segment of the Human Granulocyte Colony-stimulating Factor market is another essential aspect of Human Granulocyte Colony-stimulating Factor segmentation. This category includes various subtypes, such as filgrastim and lenograstim, which are used to stimulate the production of white blood cells in the body. The types segment is vital in understanding the market dynamics, as each subtype has its own set of characteristics, advantages, and disadvantages, influencing the overall market size and growth trajectory.

Human Granulocyte Colony-stimulating Factor Segmentation Breakdown8 items

Application

Hospital

Clinic

Types

300μg/Dose

150μg/Dose

75μg/Dose

Others

Regional Insights

Loading chart…

The Human Granulocyte Colony-stimulating Factor market growth is expected to vary across regions, with Asia Pacific being the largest region, accounting for approximately 40% of the global market, and also the fastest-growing region. Key drivers for Asia Pacific include increasing adoption of Human Granulocyte Colony-stimulating Factor, government policies supporting the development of biotechnology, and significant investments in healthcare infrastructure.

In North America, key drivers include a mature ecosystem, high demographics of cancer patients, and significant investments in research and development. Europe is driven by a strong infrastructure for biotechnology research, favorable policies for pharmaceutical development, and a high adoption rate of Human Granulocyte Colony-stimulating Factor. Latin America and Middle East & Africa are driven by growing demand for biopharmaceuticals, increasing investments in healthcare, and improving infrastructure.

The regional forecast indicates that Asia Pacific will continue to dominate the Human Granulocyte Colony-stimulating Factor market, driven by its large patient population, increasing adoption of biopharmaceuticals, and significant investments in healthcare. As the market continues to evolve, understanding the key drivers and trends in each region will be crucial for businesses to capitalize on the growth opportunities in the Human Granulocyte Colony-stimulating Factor market.

Competitive Landscape

The Human Granulocyte Colony-stimulating Factor market is moderately consolidated, driven by a mix of global players and local companies. The Human Granulocyte Colony-stimulating Factor competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and regulatory approvals, while local companies emphasize distribution and pricing strategies.

Companies employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and commoditization. To stay competitive, companies must develop unique value propositions, leveraging technology, service models, channel strength, customization, and cost advantages. The following companies have distinct strategic focuses:

Chugai Pharmaceutical: regional expansion

Kyowa Hakko Kirin: innovation pipeline

Sanway: local manufacturing

GenSci: premium pricing

SL PHARM: OEM tie-ups

Kexing Bioproducts: vertical integration

Key Human Granulocyte Colony-stimulating Factor Companies15 items

Chugai Pharmaceutical

Kyowa Hakko Kirin

Sanway

GenSci

SL PHARM

Kexing Bioproducts

Qilu Pharmaceutical

CSPC

Wuzhong Pharmaceutical

Quangang Pharmaceutical

Huabei Pharmaceutical

Harbin Pharmaceutical

Amoytop Biotech

Jiuyuan Gene Engineering

Four Rings Biopharmaceutical

Market Ecosystem

The Human Granulocyte Colony-stimulating Factor ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. Value is created and captured through the development, manufacturing, and distribution of Human Granulocyte Colony-stimulating Factor products. The ecosystem is characterized by a complex interplay of participants, each playing a distinct role in the value chain analysis.

Raw material suppliers — providing critical components

OEMs / manufacturers — producing Human Granulocyte Colony-stimulating Factor products

Technology providers — developing underlying technologies

Distributors / channel partners — facilitating product distribution

Service providers / after-sales — offering support and maintenance services

End users / buyers — utilizing Human Granulocyte Colony-stimulating Factor products

Regulators/standards bodies — establishing guidelines and approvals

The flow of value in the Human Granulocyte Colony-stimulating Factor ecosystem is influenced by control points, such as regulatory approvals and standards, which can create bottlenecks and impact adoption. Dependency risks, including input constraints and switching costs, can also affect the ecosystem. Furthermore, partnerships and interoperability requirements can facilitate or hinder the exchange of value among participants. The ecosystem's dynamics can vary by region, with different areas having distinct regulatory frameworks, market conditions, and participant interactions.

Recent Industry Insights

The Human Granulocyte Colony-stimulating Factor industry trends have witnessed significant developments over the last 12-18 months. Notably, there have been several strategic partnerships aimed at enhancing research and development capabilities, as well as mergers and acquisitions that have led to market consolidation. Furthermore, the launch of new products and technologies has expanded treatment options for patients. Regulatory changes have also played a crucial role in shaping the industry, with a greater emphasis on safety and efficacy. A shift in consumer trends towards more personalized and targeted therapies has driven innovation, while funding rounds and expansions have enabled companies to invest in promising research and development projects.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Human Granulocyte Colony-stimulating Factor market. The market attractiveness is moderate, driven by increasing demand for effective treatments of chemotherapy-induced neutropenia. The competitive intensity is high, with multiple players competing for market share. The long-term outlook for the Human Granulocyte Colony-stimulating Factor market outlook is promising, with opportunities for growth in emerging markets.

The innovation landscape is evolving, with a focus on biosimilars and biologics. The demand–supply balance is stable, with key players ensuring adequate supply to meet growing demand. However, key risk factors include regulatory changes and pricing pressures. Overall, the market is expected to experience steady growth, driven by increasing adoption of Human Granulocyte Colony-stimulating Factor therapies.

11 items

1. Executive Summary

2. Human Granulocyte Colony-stimulating Factor Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Human Granulocyte Colony-stimulating Factor Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Human Granulocyte Colony-stimulating Factor Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Clinic

6.2. Global Human Granulocyte Colony-stimulating Factor Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. 300μg/Dose

6.2.2. 150μg/Dose

6.2.3. 75μg/Dose

6.2.4. Others

6.3. Global Human Granulocyte Colony-stimulating Factor Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Human Granulocyte Colony-stimulating Factor Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Human Granulocyte Colony-stimulating Factor Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Human Granulocyte Colony-stimulating Factor Market Competition by Key Manufacturers

8.1. Global Human Granulocyte Colony-stimulating Factor Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Human Granulocyte Colony-stimulating Factor: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Chugai Pharmaceutical

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Kyowa Hakko Kirin

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Sanway

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. GenSci

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. SL PHARM

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Kexing Bioproducts

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Qilu Pharmaceutical

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. CSPC

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Wuzhong Pharmaceutical

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Quangang Pharmaceutical

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Huabei Pharmaceutical

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Harbin Pharmaceutical

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Amoytop Biotech

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Jiuyuan Gene Engineering

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Four Rings Biopharmaceutical

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Human Granulocyte Colony-stimulating Factor Market

Figure 4: Global Human Granulocyte Colony-stimulating Factor Market: Drivers

Figure 5: Global Human Granulocyte Colony-stimulating Factor Market: Challenges

Figure 6: Global Human Granulocyte Colony-stimulating Factor Market: Trends

Figure 7: Global Human Granulocyte Colony-stimulating Factor Market: Opportunity

Figure 8: Global Human Granulocyte Colony-stimulating Factor Market: Restraint

Figure 9: Global Human Granulocyte Colony-stimulating Factor Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Human Granulocyte Colony-stimulating Factor Market Value (USD Million) By Region

Figure 15: Global Human Granulocyte Colony-stimulating Factor Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Human Granulocyte Colony-stimulating Factor Market Value (USD Million) By Region

Figure 23: Global Human Granulocyte Colony-stimulating Factor Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

83 items

Table 1: Market Segmentation Analysis

Table 2: Global Human Granulocyte Colony-stimulating Factor Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Human Granulocyte Colony-stimulating Factor Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Human Granulocyte Colony-stimulating Factor Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Human Granulocyte Colony-stimulating Factor Market Value (USD Million) By Region

Table 10: Global Human Granulocyte Colony-stimulating Factor Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Human Granulocyte Colony-stimulating Factor Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Human Granulocyte Colony-stimulating Factor Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Human Granulocyte Colony-stimulating Factor Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Chugai Pharmaceutical Basic Information And Sales Area

Table 31: Chugai Pharmaceutical. Products Portfolio

Table 32: Kyowa Hakko Kirin Basic Information And Sales Area

Table 33: Kyowa Hakko Kirin. Products Portfolio

Table 34: Sanway Basic Information And Sales Area

Table 35: Sanway. Products Portfolio

Table 36: GenSci Basic Information And Sales Area

Table 37: GenSci. Products Portfolio

Table 38: SL PHARM Basic Information And Sales Area

Table 39: SL PHARM. Products Portfolio

Table 40: Kexing Bioproducts Basic Information And Sales Area

Table 41: Kexing Bioproducts. Products Portfolio

Table 42: Qilu Pharmaceutical Basic Information And Sales Area

Table 43: Qilu Pharmaceutical. Products Portfolio

Table 44: CSPC Basic Information And Sales Area

Table 45: CSPC. Products Portfolio

Table 46: Wuzhong Pharmaceutical Basic Information And Sales Area

Table 47: Wuzhong Pharmaceutical. Products Portfolio

Table 48: Quangang Pharmaceutical Basic Information And Sales Area

Table 49: Quangang Pharmaceutical. Products Portfolio

Table 50: Huabei Pharmaceutical Basic Information And Sales Area

Table 51: Huabei Pharmaceutical. Products Portfolio

Table 52: Harbin Pharmaceutical Basic Information And Sales Area

Table 53: Harbin Pharmaceutical. Products Portfolio

Table 54: Amoytop Biotech Basic Information And Sales Area

Table 55: Amoytop Biotech. Products Portfolio

Table 56: Jiuyuan Gene Engineering Basic Information And Sales Area

Table 57: Jiuyuan Gene Engineering. Products Portfolio

Table 58: Four Rings Biopharmaceutical Basic Information And Sales Area

Table 59: Four Rings Biopharmaceutical. Products Portfolio

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Market Value (USD Million) (2025-2032) By Types

Table 63: Global Market Share (%) By Types (2032)

Table 64: Global Human Granulocyte Colony-stimulating Factor Market Value (USD Million) By Region

Table 65: Global Human Granulocyte Colony-stimulating Factor Market Share (%) By Region (2025-2032)

Table 66: North America Market Value (USD Million) (2025-2032) By Country

Table 67: North America Market Value (USD Million) (2025-2032) By Application

Table 68: North America Market Value (USD Million) (2025-2032) By Types

Table 69: Europe Market Value (USD Million) (2025-2032) By Country

Table 70: Europe Market Value (USD Million) (2025-2032) By Application

Table 71: Europe Market Value (USD Million) (2025-2032) By Types

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 75: South America Market Value (USD Million) (2025-2032) By Country

Table 76: South America Market Value (USD Million) (2025-2032) By Application

Table 77: South America Market Value (USD Million) (2025-2032) By Types

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 81: Research Programs/Design For This Report

Table 82: Key Data Information From Secondary Sources

Table 83: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Human Granulocyte Colony-stimulating Factor Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.61 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Chugai Pharmaceutical; Kyowa Hakko Kirin; Sanway; GenSci; SL PHARM; Kexing Bioproducts; Qilu Pharmaceutical; CSPC; Wuzhong Pharmaceutical; Quangang Pharmaceutical; Huabei Pharmaceutical; Harbin Pharmaceutical; Amoytop Biotech; Jiuyuan Gene Engineering; Four Rings Biopharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options